Literature DB >> 12362931

The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.

Kimiko Tsutsumi1, Tsutomu Kotegawa, Masae Kuranari, Yasukiyo Otani, Takuya Morimoto, Shunji Matsuki, Shigeyuki Nakano.   

Abstract

Several case reports have suggested an interaction between digoxin and macrolide antibiotics. The authors investigated the effect of erythromycin and clarithromycin on the pharmacokinetics of intravenously administered digoxin (0.5 mg) in healthy subjects. Nine male subjects participated in three studies (digoxin alone, digoxin with erythromycin, and digoxin with clarithromycin). Subjects took erythromycin (800 mg per day) or clarithromycin (400 mg per day) on the day before digoxin dosing and during the kinetic study, Neither of the macrolides affected serum digoxin concentration-time curves. However, more than 1.3-fold increases in urinary digoxin excretions were observed during erythromycin and clarithromycin coadministration compared with digoxin alone. There were significant differences in renal clearance between macrolide coadministration and the control condition (digoxin alone: 98.4 ml/min; digoxin with erythromycin: 137.3 ml/min; digoxin with clarithromycin: 133.6 ml/min). In conclusion, neither erythromycin nor clarithromycin has a significant effect on serum digoxin disposition after an intravenous administration. Renal digoxin excretion is not inhibited but rather enhanced by both macrolides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362931     DOI: 10.1177/009127002401382641

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

2.  PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Authors:  Nina Hanke; Sebastian Frechen; Daniel Moj; Hannah Britz; Thomas Eissing; Thomas Wendl; Thorsten Lehr
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-09-07

3.  Possible digoxin toxicity associated with concomitant ciprofloxacin therapy.

Authors:  Brady S Moffett; Santiago O Valdes; Jeffrey J Kim
Journal:  Int J Clin Pharm       Date:  2013-07-19

4.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Authors:  Shufeng Zhou; Eli Chan; Xiaotian Li; Min Huang
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

5.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.